Identifying potential monkeypox virus inhibitors: an in silico study targeting the A42R protein
Monkeypox (now Mpox), a zoonotic disease caused by the monkeypox virus (MPXV) is an emerging threat to global health. In the time span of only six months, from May to October 2022, the number of MPXV cases breached 80,000 and many of the outbreaks occurred in locations that had never previously repo...
Main Authors: | Carolyn N. Ashley, Emmanuel Broni, Chanyah M. Wood, Tunmise Okuneye, Mary-Pearl T. Ojukwu, Qunfeng Dong, Carla Gallagher, Whelton A. Miller |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2024-03-01
|
Series: | Frontiers in Cellular and Infection Microbiology |
Subjects: | |
Online Access: | https://www.frontiersin.org/articles/10.3389/fcimb.2024.1351737/full |
Similar Items
-
Comprehensive update on the monkeypox outbreak
by: Asad Mustafa Karim, et al.
Published: (2022-11-01) -
A Glance at the Development and Patent Literature of Tecovirimat: The First-in-Class Therapy for Emerging Monkeypox Outbreak
by: Mazen Almehmadi, et al.
Published: (2022-08-01) -
Human monkeypox: a comparison of the characteristics of the new epidemic to the endemic disease
by: Sharon Sukhdeo, et al.
Published: (2022-12-01) -
Monkeypox - review
by: Aleksandra Amalia Kuchnicka, et al.
Published: (2022-08-01) -
[Translated article] RF – Potential Treatments for Monkeypox
by: F.J. Rodríguez-Cuadrado, et al.
Published: (2023-07-01)